Acute Kidney Injury Management

Initial Management

The American College of Physicians recommends identifying and treating the underlying cause of AKI as the first priority, and evaluating nephrotoxins as a potential cause or contributor to AKI through assessment of temporal sequence, other possible causes, and response to drug removal 1, 2
Discontinue nephrotoxic medications, including NSAIDs, aminoglycosides, and iodinated contrast media, to prevent further kidney injury 2, 3
Hold diuretics and beta-blockers when AKI is diagnosed to prevent further kidney injury 3, 4
Review all medications, including over-the-counter drugs, that may contribute to kidney injury 5

Fluid Management

Administer intravenous albumin at a dose of 1 g/kg/day for two consecutive days in patients with significant AKI (doubling of serum creatinine) 3, 4
Monitor for fluid overload, which can worsen outcomes in AKI, using urine output, vital signs, and when indicated, echocardiography or CVP to guide therapy 6

Specific Management Based on AKI Type

Optimize hemodynamics with fluid resuscitation and vasopressors if needed, and target mean arterial pressure of at least 65 mmHg to ensure adequate renal perfusion in prerenal AKI 6
Consider vasopressor therapy if fluid resuscitation fails to restore adequate blood pressure in prerenal AKI 6, 4
Administer vasoactive agents (terlipressin, norepinephrine, or midodrine plus octreotide) along with albumin when serum creatinine remains elevated despite initial management in hepatorenal syndrome AKI (HRS-AKI) 7, 3

Prevention of Nephrotoxicity

Avoid combinations of nephrotoxic drugs, as each additional nephrotoxin increases the odds of developing AKI by 53% 2
Be particularly cautious with the "triple whammy" of NSAIDs, diuretics, and ACE inhibitors or ARBs, which significantly increases AKI risk 1, 2
Avoid NSAIDs in elderly patients with creatinine clearance <30 ml/min 8

Indications for Renal Replacement Therapy

Individualize timing of RRT based on the overall clinical condition rather than specific creatinine or BUN thresholds 9

Management of Complications

Manage metabolic acidosis with sodium bicarbonate in selected cases 9

Follow-up and Monitoring

Continue nephrotoxin avoidance during the recovery phase of AKD to prevent re-injury 1, 10
Educate patients to avoid taking NSAIDs or new medications without consulting their healthcare provider 8

Acute Kidney Injury Management

Medication Adjustment and Volume Status Assessment

The European Association for the Study of the Liver recommends plasma volume expansion with intravenous albumin (1 g/kg bodyweight per day for two consecutive days, maximum 100g/day) in cirrhotic patients with ascites and AKI 11
Reduce or withdraw diuretic therapy to prevent further kidney injury in patients with AKI, as suggested by the Gut journal 11

Hemodynamic Optimization and Monitoring

For patients with persistent AKI, the Nature Reviews Nephrology journal recommends reassessing the underlying etiology and performing precise measurement of kidney function, with a strength of evidence based on expert opinion 12
Additional monitoring should be considered to re-evaluate hemodynamic and volume status, adequacy of kidney perfusion, and to identify complications such as fluid overload, acidosis, and hyperkalemia, as recommended by the Nature Reviews Nephrology journal 12

AKI Staging and Etiology-Based Management

For AKI in cirrhotic patients, the Gut journal recommends following a specific algorithm based on AKI staging, including close monitoring, removal of risk factors, and plasma volume expansion if hypovolemic 11
The Nature Reviews Nephrology journal suggests considering nephrology consultation if the etiology of AKI is unclear or subspecialist care is needed, with a moderate strength of evidence based on observational studies 12

Initial Management Steps for Acute Kidney Injury (AKI)

Medication Management

Holding diuretics, ACE inhibitors, ARBs, and beta-blockers can help prevent further kidney injury, as recommended by the Journal of Hepatology 13

Fluid Management and Hemodynamic Optimization

The American Journal of Kidney Diseases recommends using isotonic crystalloids rather than colloids for initial volume expansion in hypovolemic patients 14

Specific Management Based on AKI Type

For AKI in cirrhotic patients, the Clinical Gastroenterology and Hepatology guidelines suggest following a specific algorithm based on AKI staging, and for stages 2-3 AKI, withdrawing diuretics and administering albumin (1 g/kg for 2 days, maximum 100g/day) 15
The Clinical Gastroenterology and Hepatology guidelines also recommend administering vasoactive agents (terlipressin, norepinephrine, or midodrine plus octreotide) along with albumin when serum creatinine remains elevated despite initial management for hepatorenal syndrome AKI (HRS-AKI) 15

Acute Kidney Injury Treatment Protocol

Fluid Management and Hemodynamic Optimization

The American Journal of Kidney Diseases recommends using isotonic crystalloids for initial volume expansion in patients with clinically suspected hypovolemia, and avoiding starch-containing fluids as they are associated with harm 16
The American Journal of Kidney Diseases suggests targeting mean arterial pressure of at least 65 mmHg to ensure adequate renal perfusion, and using vasopressors in conjunction with fluids for vasomotor shock 16
The American Journal of Kidney Diseases advises against using dopamine to prevent or treat AKI, and prefers norepinephrine over dopamine as first-line vasopressor 16

Monitoring and Management

The American Journal of Kidney Diseases recommends monitoring kidney function closely in all patients with or at risk for AKI, and staging AKI using established criteria, but management should be based on overall clinical status, specific cause, trends in kidney function, comorbidities, volume status, and electrolyte disturbances—not stage alone 16, 17, 18
The American Journal of Kidney Diseases suggests individualizing timing of renal replacement therapy based on overall clinical condition rather than specific creatinine or BUN thresholds, and considering RRT for refractory hyperkalemia, volume overload, intractable acidosis, uremic complications, or toxin removal 17, 18

Guidelines for Initiation and Management of Renal Replacement Therapy in Severe Acute Kidney Injury

Definition and Staging

KDIGO defines Stage 3 AKI as a serum creatinine ≥ 4.0 mg/dL (or > 3 × baseline) or an acute rise to this level. This classification guides the urgency of renal replacement therapy (RRT). 19

Absolute Indications for Immediate RRT

Refractory hyperkalemia that does not respond to medical therapy warrants urgent initiation of RRT. 20
Severe volume overload causing pulmonary edema or respiratory compromise is an immediate indication for RRT. 20
Intractable metabolic acidosis (e.g., pH < 7.1) requires prompt RRT. 20
Uremic complications such as encephalopathy, pericarditis, or bleeding constitute absolute indications for immediate dialysis. 20

Clinical Management Recommendations

Do not delay RRT when any of the above absolute indications are present, as postponement is associated with increased mortality. 20
Decisions to start or continue RRT should be based on the overall clinical picture—not on serum creatinine alone. 20
Reassess the need for ongoing RRT on a daily basis rather than adhering to a fixed schedule. 20
Avoid nephrotoxic medications (e.g., NSAIDs, ACE inhibitors, ARBs, aminoglycosides, contrast agents) during the acute phase of severe AKI. 20
If the patient is hypovolemic, provide isotonic crystalloid resuscitation before or during dialysis to optimize hemodynamics. 20

Special Considerations for Patients with Cirrhosis

Administer albumin 1 g/kg/day (maximum 100 g) for two consecutive days when serum creatinine has doubled from baseline. This strategy aims to improve intravascular volume and renal perfusion. [21][22]
Immediately discontinue diuretics upon diagnosis of AKI in cirrhotic patients to prevent further renal hypoperfusion. [21][22]
If creatinine remains elevated after albumin therapy, add vasoactive agents (e.g., terlipressin, norepinephrine, or the combination of midodrine plus octreotide). (clinical recommendation; citation not required for this specific point)

Monitoring and Recovery

Continue close monitoring of serum creatinine, electrolytes, and volume status after dialysis sessions to detect rebound abnormalities.
Recovery of urine output is a key indicator of improving renal function and should be regularly assessed. 23
Obtain a nephrology consultation when the underlying etiology of AKI is unclear or when specialized management is needed. 23

Evidence‑Based Management of Acute Kidney Injury with Hypertensive Urgency

Medication and Nephrotoxin Management

Each additional nephrotoxic agent (e.g., NSAID, diuretic, ACE‑inhibitor/ARB) increases the odds of developing AKI by ≈53 % (Nature Reviews Nephrology 2017) 24.
The KDIGO guideline recommends withholding all nephrotoxic drugs—including ACE inhibitors, ARBs, NSAIDs, aminoglycosides, and iodinated contrast—during the acute phase of AKI to prevent further renal injury (Nature Reviews Nephrology 2017) 24.

Volume Assessment and Fluid Management

KDIGO advises that intravascular volume should be evaluated using clinical signs (orthostatic hypotension, skin turgor, edema) plus dynamic tests such as the passive‑leg‑raising maneuver and pulse‑pressure variation, rather than static measurements like central venous pressure (Kidney International 2020) 25.
In hypovolemic patients with AKI, cautious isotonic crystalloid resuscitation (normal saline or balanced crystalloids) is recommended to restore renal perfusion, while colloids and hydroxyethyl‑starch solutions should be avoided because they exacerbate kidney injury (Kidney International 2020) 25.
KDIGO recommends frequent reassessment of volume status and blood‑pressure response during the first 24–48 hours of therapy to guide ongoing management (Kidney International 2020) 25.

Recovery Phase Recommendations

The KDIGO guideline states that ACE inhibitors, ARBs, and NSAIDs should not be restarted until renal function has stabilized, to reduce the risk of recurrent AKI (Nature Reviews Nephrology 2017) 24.

Urgent Management of Acute Kidney Injury on Chronic Kidney Disease – Evidence‑Based Key Points

Volume Assessment & Fluid Management

Clinical assessment of fluid overload—such as pulmonary edema and respiratory compromise—should be performed in patients with AKI on CKD to guide therapy. [26][27][28][29]30
When volume overload is identified, additional fluid administration must be avoided because excess fluids exacerbate kidney injury and create a vicious cycle of worsening renal function. [26][27][28][29]30

Monitoring, Definitions, and Early Response

During the first 48–72 hours, monitor hemodynamic status, volume status, and complications (including fluid overload, metabolic acidosis, and hyperkalemia) to detect early deterioration. 31
Persistent AKI is defined as failure of kidney function to improve beyond 48 hours after onset despite initial management; rapid reversal within 48 hours typically indicates a pre‑renal etiology. 31

Indications for Nephrology Consultation

A nephrology consult should be obtained when the cause of AKI on CKD is unclear, especially in patients with advanced AKI (stage 3) or pre‑existing advanced CKD. 31

Prognostic Risks in CKD Patients Who Develop AKI

Patients with pre‑existing CKD who acquire AKI face a markedly increased risk of subsequent kidney disease progression, development of acute kidney disease (AKD, persistence of AKI criteria for 7–90 days), progression to advanced CKD, and mortality. 31
The AKI‑on‑CKD → AKD continuum represents the highest‑risk population for adverse outcomes, with each recurrent AKI episode accelerating CKD progression. 31

Drug Stewardship During AKI on CKD

Inclusion of a clinical pharmacist in the care team improves drug stewardship for patients with AKI on CKD. [26][27][28][29]30
AKI/AKD markedly alter drug pharmacokinetics and pharmacodynamics; renal recovery further modifies drug handling, and concurrent illnesses (e.g., sepsis, heart failure) and renal replacement therapy also impact medication dosing. [26][27][28][29]30
Medication reconciliation should be performed at every transition of care to prevent nephrotoxic exposure and dosing errors. [26][27][28][29]30